Theralase Technologies, Inc. engages in the design, development, and manufacture of patented laser technology platforms used in bio-stimulative and bio-destructive clinical applications in patients. It operates through the Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT) segments. The ACT segment covers the research and development of photo dynamic compounds (PDCs) for the treatment of cancer. The CLT segment is responsible for the company’s medical laser business, which researches, develops, manufactures, and distributes CLT systems to healthcare practitioners predominantly for the healing of pain. The company was founded by Roger J. Dumoulin-White on August 22, 1989 and is headquartered in Toronto, Canada.